S. Lim

Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Clive M. Onnie, R. Vega, E. Seward, 2022, Frontline Gastroenterology.

Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all‐cause admissions in patients on the liver transplant waiting list

N. Heaton, M. Heneghan, V. Patel, 2019, Alimentary pharmacology & therapeutics.

Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.

C. Lees, D. Gaya, J. Lindsay, 2023, Inflammatory bowel diseases.